Introduction
The leading cause of cancer death in the Western world is lung cancer. Despite major advances over the past 40 years in the fields of surgery, radiotherapy and chemotherapy, the lung cancer failure rate remains unacceptably high. The majority of patients with lung cancer (75%) are within the non-small-cell lung cancer (NSCLC) category. This type of cancer can be subdivided into adenocarcinoma, squamous cell carcinoma and large-cell undifferentiated carcinoma. In general, 25%-30% of the NSCLC patients present with tumours confined to the lung (stages I or II), 30% have locally advanced disease (stage Ilia and b) and the remaining 40%-45% have distant metastases (stage IV) [1] . In spite of radical surgery and additional treatment with chemotherapy and/or irradiation, less than 40% of the patients with stages I and II disease will survive 5 years or more and for stage Ula and b much more modest survival figures (8%) are anticipated [2] .
In the majority of NSCLC cases, the tumour will be located in the central part of the tracheobronchial tree [3] (see Fig. 1 ). It is therefore not surprising that patients often present with complaints such as dyspnea, hemoptysis, infection or stridor.
External irradiation therapy has been used as a standard treatment to ameliorate these symptoms. Palliation by radiotherapy, however, is frequently of relatively short duration and many patients will suffer from local recurrence [4] . For these patients and those with significant impairment of pulmonary function, endobronchial treatments are increasingly important not only for palliation but occasionally also for cure of NSCLC. This article presents an overview of the available therapeutic modalities and their indications.
Endobronchial laser treatment
The acronym LASER stands for Light Amplification by Stimulated Emission of Radiation. Laser light is bundled light of a single wavelength (monochromatic) and phase, with a high intensity. Since 1980, the development of more practical and powerful lasers has enabled its more extensive use in medicine.
CO 2 laser
The CO 2 laser, which has been used extensively in ENT (Ear, Nose and Throat) treatments and in gynecology, is the best known laser. The wavelength used, 10,600 nm, allows it to cut tissue with a limited depth of penetration (2-3 mm) (Fig. 2) . To transfer energy from the laser to the working site, a system consisting of a rigid tube with mirrors is required. It can be used in the tracheo-bronchial tree for polypoid lesions which are located centrally. Due to the rigid guidance system, lesions which are located more distally, or in some of the second-generation bronchi, cannot be treated. One of the disadvantages is that the procedure has to be performed using general anesthesia and a rigid bronchoscope [5] , although a more flexible system is currently being developed [6] . One of the attractions of the CO 2 laser is that it allows accurate cutting of tissues. 
Argon-ion laser
The argon laser (480-520 nm) was initially used to stop bleeding of tumours [7] . The wavelength is absorbed mainly by hemoglobin and therefore has a limited penetration depth in tissue, thus precluding complications (Fig. 2) . The argon laser is expensive and especially difficult to handle when higher energies are required. The laser light can be transported by flexible fibers which enables their use in a fibre-optic bronchoscope, allowing treatments up to the subsegmental airway level. Since the hemoglobin and pigmented tissue strongly absorb the argon laser beam, its applicability in the 480-520 nm range is limited to the treatment of port-wine lesions, telangiectasia, retinal diseases and removal of tattoos. Although the argon laser is used frequently in ophthalmology and dermatology, it has only a very limited application in lung cancer. It might, however, be indicated for the treatment of superficial, early tumours in the lung. Another disadvantage is its low efficiency (approximately 0.1% of the energy is available for effective treatment). The brightness of the laser light renders the use of goggles imperative.
Nd-YAG laser
The Neodymium Yttrium Aluminum Garnet laser (Nd-YAG) is the laser most often used to remove obstructions from the trachea and central bronchi. The laser emits at a wavelength of 1,064 nm (infra-red light; Fig. 2 [3, [8] [9] [10] [11] [12] ]. An overview of some large treatment series is presented in Table 1 . All patients suffered from endobronchial obstruction to various degrees. In the majority of the cases, the indication for laser treatment is restoration of the airway patency or, less frequently, management of bleeding lesions. Although respiration can be improved after treatment, Brutinel [13] observed that patients can experience hypoxia during treatment probably due to smoke inhalation, inflammation and oedema. The penetration depth of the YAG laser varies from superficial to 1 cm, depending on the power setting. The treatment therefore carries the risk of perforating the normal bronchial wall, and causing fatal hemorrhage, pneumothorax, oesophageal-bronchial fistulas and even fire in the tracheo-bronchial tree [14] [15] [16] [17] . It is therefore important that this treatment be applied only in centers where regular treatment sessions take place and the physician is skillful and well informed about the anatomy of the bronchial tree and mediastinal structures. If bronchial obstruction and a telectasis has already been present for several weeksjt is advisable to perform a nuclear perfusion scan before laser intervention, to avoid restoration of the airway in the absence of (adequate) vascularization. This could otherwise lead to the development of increased dead space ventilation. Although the treatment can be given using local anaesthesia and by flexible bronchoscope, we and others [18] recommend general anaesthesia and the use of a rigid bronchoscope as being safer and more complete. The advantages and contra-indications of YAG laser treatment are presented in Table 2 [17] .
Endobronchial irradiation (Brachytherapy)
In brachytherapy, a radioactive source is placed in or near the tumour to deliver a high local radiation dose. For the treatment of centrally located NSCLC, conventional external radiation techniques often fail to achieve satisfactory local control or prolonged survival [4] . Since the 1960s, intra-operative interstitial radiation sources have been applied in an attempt to achieve an improved restoration of occluded bronchi with associ- ated atelectasis or hemoptysis [19] . Various radioactive sources, such as cobalt-60, radon-222, gold-198 and iodine-125 have been used for implantation. Depending on the energy of the source (isotope) and its halflife, exposures times vary from 2 to 60 hours [20] . Intra-operative irradiation has never been widely accepted due to the complicated procedures and potential high level of exposure of the medical personnel involved in such procedures [21] [22] [23] . During the past 15 years, advanced computer controlled afterloading devices have been developed which enable accurate irradiation of endoluminal tumours with high doses of radiation (HDR). The treatment is often given as palliation and is especially suitable in cases where the tumour regrows after external irradiation therapy or when external radiation is believed to be too hazardous (pulmonary-or cardiac-compromised patients).
Iridium-192 sources (20 Ci) are most commonly used for HDR. The small size of the iridium source permits the use of a flexible bronchoscope to place a hollow (guidance) catheter with a maximum diameter 4 mm. A small iridium seed is transported, under computer control, via the catheter to the tumour area; this seed can irradiate over a length of 3 to 20 cm [24, 25] . For a 5 cm long tumour, a margin of 1 cm is usually taken. The dwell time varies from 5 to 15 minutes to obtain a dose of 10 Gray at 1 cm distance from the source. Nowadays, irradiation schemes vary from 1 x 20 Gray to 4 x 6.25 Gray, at 1 cm distance from the source, for treatment of tumours with palliative or more curative intent, respectively. HDR can also be combined with external radiation [26, 27] . In Table 3 an overview of the results of HDR in NSCLC is presented. Its advantages and disadvantages are presented in Table 2 . Of the complications of this treatment, airway stenosis is most frequently observed, and hemorrhage, fistulation and infection less frequently.
For low-dose rate irradiation (LDR) caesium-137 or a low energy source of iridium-192 can be used. The catheter must remain in the bronchi for a prolonged period (2 to 60 hrs) to provide an adequate dose of irradiation (30-50 Gray at 0.5 cm distance from the source). Intermediate dose rates, in which a slightly higher energy source is used, also require prolonged irradiation times. The procedure improves survival and also reduces the need for repeated Nd-YAG laser treatments [28, 29] .
Photodynamic therapy
Photodynamic therapy (PDT) is a relatively new local treatment modality which has shown considerable advantages with respect to the preservation of normal tissue. In 1900, Raab was the first to observe a photochemical effect on paramecia. Paramecia held in a dye solution were killed upon exposure to light. It was not until the 1960s that a hematoporphyrin derivative was found to produce fluorescence when given to a patient with a mammary carcinoma. The basic principle of photodynamic therapy is shown in Fig. 3 . After administration of a photosensitizer (local or systemic), the photosensitizer is retained with some preference in tumour tissue. The photosensitizer can be excited to a singlet or triplet state with light of a specific wavelength (coinciding with an absorption peak of the photosensitizer). In the presence of oxygen, a type II reaction can then occur, resulting in the formation of highly toxic singlet oxygen [30] . Other substrates can absorb the energy to a lesser extent, causing the formation of free radicals [31] [32] [33] [34] [35] .
Many cellular targets have been identified which are involved in the PDT reaction. Cell membranes, mitochondria and DNA can be irreversibly damaged by singlet oxygen [36] [37] [38] [39] . In addition to direct tumour cell kill, endothelial cells of the vasculature have been identified as important targets of PDT damage. This leads to vasoconstriction followed by stasis and throm- Fig. 3 . A schematic view of the basic principles of photodynamic therapy is shown. Intense (laser) light is transmitted via fiber optics to the tumour located in the bronchial tree. The interaction of this light with the retained photosensitizer will lead, in the presence of oxygen, to the formation of highly reactive singlet oxygen, resulting in tumour cell kill and vascular occlusion.
bosis in the vessels, resulting in hypoxia and secondary tumour cell kill [40] [41] [42] [43] [44] . In the 1980s, a more active fraction of hematoporphyrin derivative, named Photofrin (Quadra Logic Technologies, Vancouver, Canada) was prepared; this is now registered in Canada, The Netherlands and Japan. For an optimal PDT treatment with Photofrin, a wavelength of 630 run must be applied to obtain both a photochemical reaction and tissue penetration up to 8 mm [45] . Due to the preferential retention of the photosensitizer in the tumour and the local application of the laser light, damage to normal tissue is very limited. This is in contrast to surgical or radiation treatment, in which a significant amount of normal tissue is removed or damaged. Unfortunately, the photosensitizer Photofrin is also retained in the normal skin and, depending on the dosage used, renders the patients highly sensitive to sunlight. For a period of 4 to 6 weeks direct exposure to intense light sources is prohibited to preclude grades I or II sunburn. The development of flexible quartz fibers which can transmit the laser light has rendered it possible to treat patients with PDT using flexible bronchoscopy under local anesthesia. Specific light applicators (cylindrical diffusers, bulb-fibers, microlens, see Fig. 4 ) have been developed to allow homogeneous illumination of the tumour. The advantages and disadvantages of endobronchial PDT are presented in Table 2 . The efficacy of photodynamic therapy in NSCLC for palliation and curative treatment of 'early cancer" has been the subject of several phase II studies [46] [47] [48] [49] [50] [51] [52] [53] (Table 4) . Studies performed by Hayata [54] , Kato [55] , Edell [48, 49] and Cortese [56] have shown that complete remissions can be achieved by PDT alone and it is now becoming clear that the major application for PDT is in the treatment of early cancer lesions, especially in patients in Microlens Bulbfiber Cylindrical Fig. 4 . Three different types of light applicators are shown. Microlens fibers can be used for superficial treatment, bulb fibers are used to treat hollow organs like the bladder and cylindrical fibers are used for the treatment of cylindrical organs like bronchus and esophagus or applied intra-tumorally. whom tissue preservation is of paramount importance. Although significant desobstruction of the airways can be achieved by PDT, the palliative effect of this treatment modality is hampered by skin phototoxicity. To overcome this problem other photosensitizers with a shorter half-life or better tumour-versus-normal-tissue retention are being tested in phase I and II studies. Complications such as haemorrhage and respiratory distress have been addressed and may be avoided by appropriate patient selection (exclusion of patients with evidence of tumour invasion of the major vessels or post pneumonectomy lesions). The treatment itself can be applied to all types of cancer as long as adequate light delivery can be achieved.
Diathermy and cryotherapy
These techniques are still frequently used in gastroenterology or dermatology but the indication for their use in the treatment of endobronchial obstructions is limited. Diathermy can be used as an adjunct to Nd-YAG laser therapy or endobronchial irradiation. It can also be used to treat benign tumours [57] or debulk tracheal tumours before application of endobronchial irradiation. It is a relatively simple and inexpensive type of therapy. Few complications have been reported in the literature, but tracheal fire has been documented by Hooper et al. [58] . A considerable amount of smoke can be induced by the procedure.
Sanderson [59] was the first to use cryotherapy in the bronchial tree by means of a rigid bronchoscope. Initially a liquid nitrogen probe (-70 °C) was used to freeze the tumour, but nowadays nitrous oxide at a temperature of -40 °C is applied. Homasson [60] [61] [62] used flexible probes which made the application easier. A disadvantage of this technique appears to be the need for repeated treatments. 
Endobronchial stents
Endobronchial stents are protheses suitable for the expansion of trachea and/or bronchi, especially in the case of extrinsic compression of the airways. Montgomery [63] initially developed a silicone rubber T-tube for the management of tracheal or subglottic stenosis. Recently, modification of existing and new designs of stents have greatly improved the acceptance of this technique. Expandable metal wire stents (Wall stent, Palmaz, Gianturco), which were originally developed for the treatment of vascular occlusion, have become suitable for endobronchial use. After tumour resection or dilatation, the stent can be put into place under fluoroscopic guidance. After release of the guidance sheet the stent expands to a prefixed diameter varying from 1 to 2.2 cm in diameter [64] [65] [66] . The stents are usually made of shaped wire netting and, after a few days, a thin mucosal layer will grow in them. Some stents are coated and can be used in the palliative treatment of fistulas or tumours. Most expandable stents can be put in place using local anaesthesia and fluoroscopy, but the placement must be very accurate, since rearrangement of the stent is very difficult after expansion. The indication for these stents is therefore in the context of palliative treatment.
Dumon [67] developed silicone stents of different diameters with studs on the external surface. A special syringe plunger system is necessary to allow placement via a rigid bronchoscope. The stents can be removed and are therefore of value for the treatment of benign strictures. Complications are obstruction of the airway by dried secretions, granulomata or migration of the stent during excessive coughing and/or labored breathing. To overcome these problems, Freitag et al. [68] developed a dynamic stent for the tracheo-bronchial tree. It can be used in the treatment of tracheo-oesophageal fistulae and for both benign and malignant obstructions. The main limitation is that only a few different sizes are currently available. For all types of stents, an immediate relief of symptoms of airway obstruction can be achieved and further treatment with, for instance, endobroncial irradiation becomes possible.
Combined stenting of the oesophagus and trachea is sometimes required to treat side effects of stenosing esophageal tumours [69, 70] . Initial placement of a tracheal stent can prevent life-threatening airway compression by dilatation or placement of a stent in the esophagus (Fig. 5) .
Conclusions
Several endobronchial techniques have significantly enlarged the therapeutic arsenal of the pulmonary endoscopisL Depending on the treatment facilities available (endobronchial irradiation devices, laser equipment) and the interventional experience of the endoscopist, palliation can be achieved with relatively little effort and without excess normal tissue damage. Nd-YAG laser, HDR and also PDT are being increasingly used. Although the indications for these treatments overlap to some extent, the most appropriate use for Nd-YAG laser treatment is desobstruction of endobronchial tumors in patients in whom quick relief of symptoms is required. Because the tumours are perpendicular to the laser beam, almost all of them recur.
The more invasive parts of the tumour can be treated by photodynamic therapy and endobronchial irradiation, leading to less frequent recurrence.
Endobronchial irradiation can easily be given but normal tissue damage can occur, leading to bronchial stenosis, fisrulation or haemoptysis. Its major indication is palliative treatment of patients in whom other therapies are contra-indicated.
Photodynamic therapy is now focusing on the treatment of smaller rumours since light penetration in the bronchial tree is limited. Skin photosensitivity, using the current registered photosensirizer (Photofrin), is a major problem when PDT is given for palliation. Side effects encompass a possible bronchial stenosis, postobstructive infection or hemoptysis. To ameliorate the major side effect of PDT, e.g., skin phototoxicity, new photosensitizers with shorter half-lives are now being developed. Refinement of photodynamic therapy will almost certainly lead to a wider acceptance of this treatment modality, especially for 'early cancers'.
At first glance, some of the equipment and materials used (e.g., stents) appear expensive, but shorter periods in hospital for symptomatic treatment and a decreased need for supportive care have to be taken into account.
